Is Compounded Tirzepatide Still Legal in 2026? FDA Shortage Rules, 503A/503B, What Changed

Key takeaways

• Yes, compounded tirzepatide is still available, but only in a narrow lane: a state-licensed 503A pharmacy may prepare it for a named patient whose prescriber documents a change that makes a significant difference for that patient. Copies sold to everyone lost their legal basis when the shortage ended.
• FDA declared the shortage resolved on October 2, 2024, reconsidered after compounders sued, and confirmed it on December 19, 2024. The grace periods ended February 18, 2025 for pharmacies and March 19, 2025 for outsourcing facilities.
• The courts sided with FDA at every step: a Texas federal court refused an injunction in March 2025 and ruled for FDA and Lilly that spring, and the Fifth Circuit affirmed on August 27, 2026.
• 2026 was the enforcement year: 55 warning letters to telehealth marketers, letters to research-vial sellers, a September letter calling a tirzepatide-niacinamide product a copy with 'pretextual' differences, and a May 1 proposal to keep tirzepatide off the 503B list.
• Adding B12, choosing a 'personalized' dose from a menu or citing price does not turn a copy into a legal product. A real exception is documented by the prescriber, for one patient, for a clinical reason.

The short answer

Tirzepatide itself is an approved drug, sold as Mounjaro for type 2 diabetes and Zepbound for weight management and sleep apnea, and nothing about its legality has changed. The question is about compounded copies, and the answer depends on which kind.

While FDA listed tirzepatide as in shortage, federal law let pharmacies make copies of it in volume. That window closed with the shortage. Since early 2025 a compounded tirzepatide is legal only when a state-licensed 503A pharmacy prepares it for an identified patient and the prescriber has determined, and written down, that a change from the approved product makes a significant difference for that patient. Outsourcing facilities (503B) have had no basis to make it from bulk powder since March 19, 2025, and FDA has proposed to keep it that way.

What is still widely sold, a monthly subscription to compounded tirzepatide for anyone who completes a form, is the model FDA spent 2026 writing warning letters about. Our compounded tirzepatide hub covers the drug, dosing and risks; this page is the legal record, kept consistent with our peptide legal tracker.

The timeline, 2022 to 2026

How the shortage opened the door, and how it closed

December 2022 to October 2024: the shortage years

Federal law normally forbids pharmacies from regularly compounding copies of a commercially available drug, and forbids outsourcing facilities from compounding copies of approved drugs. Both restrictions lift while the drug is on FDA's shortage list. FDA added Mounjaro to the list in December 2022 and Zepbound in April 2024, and compounders filled the gap; during the same period Lilly spent about $23 billion expanding manufacturing and won approval for single-dose vials (Fifth Circuit 2026). Most of today's telehealth tirzepatide market was built in those two years.

October 2024: resolved, sued, reconsidered

On October 2, 2024 FDA posted that the shortage was resolved. On October 8 the Outsourcing Facilities Association, a trade group of 503B facilities, and FarmaKeio Custom Compounding sued in the Northern District of Texas. Three days later FDA asked the court to send the decision back so it could reevaluate it, and said it would not take enforcement action against the plaintiffs while it did so and for two weeks after (Foley, October 2024).

December 19, 2024: the final decision and the grace periods

On December 19, 2024 FDA issued a declaratory order confirming that the shortage was resolved, after collecting data from Lilly, patients, prescribers, compounders and telehealth companies. It acknowledged that patients might still see intermittent local disruptions, and set grace periods: 60 days for 503A pharmacies, to February 18, 2025, and 90 days for 503B facilities, to March 19, 2025 (Foley, December 2024). FDA concluded that Lilly's supply would meet or exceed projected demand; the record showed Lilly with a surplus at the end of every month of 2024, almost 11.6 million doses in the month before the decision (Fifth Circuit 2026).

The court fight, 2025 to 2026

The compounders argued that FDA should have used notice-and-comment rulemaking and that its supply analysis was arbitrary. On March 5, 2025 the district court denied their request for a preliminary injunction and a stay, and they appealed on March 10 (Foley, March 2025). A Fifth Circuit panel declined to disturb that denial, and on May 7, 2025 the district court ruled for FDA and Lilly on the merits (McDermott 2025), granting summary judgment on the full administrative record (Fifth Circuit 2026).

On August 27, 2026 the Fifth Circuit affirmed. Assuming without deciding that FDA should have used notice and comment, the panel held the compounders had not shown any prejudice from the procedure; and it held that FDA's reliance on Lilly's supply data, after repeatedly asking Lilly to explain its methods, was reasoned decision-making rather than arbitrary (Fifth Circuit 2026). The same panel decided the parallel semaglutide appeal the same way. The opinions are unpublished, which makes them less weighty as precedent, but they end this challenge: the shortage exception is not coming back through the courts.

2026: the enforcement year

With the legal question settled, FDA turned to marketing and to the products themselves.

• Telehealth marketing. Thirty warning letters announced March 3 accused telehealth companies of misbranding compounded GLP-1s with claims such as "Generic Zepbound" and "FDA approved active pharmaceutical ingredients", and of putting their own brand on vials in a way that implied they compounded the drug (Foley 2026). Twenty-five more, made public June 16, targeted claims of clinical proof and of products from an "FDA-approved" pharmacy, which FDA says does not exist as a category (Sheppard Mullin 2026).
• Research vials. Seven letters dated March 31, recorded in our tracker, and five dated August 24 went to online sellers of research-labeled tirzepatide and other peptides; FDA treated dosing guides, calculators and bundled bacteriostatic water as proof of human use (ArentFox Schiff 2026).
• Add-ins. On April 1 FDA updated its GLP-1 compounding policy with semaglutide plus B12 as an example of a product that can remain a copy despite the added ingredient. On September 18 it warned a large compounding pharmacy, Empower, that its tirzepatide-with-niacinamide and semaglutide-with-cyanocobalamin products were essentially copies, that the volumes suggested the claimed differences were "pretextual", and that significant-difference statements repeated verbatim or picked from a telehealth platform's menu undermine the individual judgment the law requires (Frier Levitt 2026).
• The 503B list. On May 1 FDA proposed not to add tirzepatide to the list of bulk substances outsourcing facilities may use (Federal Register, May 2026); it extended comments to July 30 (Federal Register, June 2026).

What 'patient-specific need' and 'essentially a copy' mean in practice

The statute and FDA's test

Section 503A lets a licensed pharmacist compound for an identified patient, on condition that the pharmacy does not compound "regularly or in inordinate amounts" drugs that are essentially copies of a commercially available product. A product is not a copy if it contains "a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner" (Federal Register 2018). FDA's 2018 guidance turns that into a working test: a compounded drug is generally a copy if it has the same active ingredient, the same, similar or easily substitutable strength, and the same route, unless the prescriber documents the patient-specific difference. FDA has said it generally will not act where a pharmacy fills four or fewer prescriptions of a given copy a month, and that a claimed difference that is a mere pretext does not count (Frier Levitt 2026).

The documentation is specific. FDA expects the determination on the prescription itself; if it is missing, the pharmacy may call the prescriber, confirm it and note the conversation and its date, or decline to fill (Federal Register 2018).

What does not qualify

• Price. In its 503B analysis FDA said it does not consider the cost of a compounded drug compared with the approved one, or convenience, when judging clinical need (Federal Register, May 2026). Our tracker records the same position for 503A: price or availability alone is not a need.
• A routine add-in. B12, B6, niacinamide or glycine added to every vial does not make a product different for any particular patient. A survey of compounding websites in early 2025 found 33 products that differed from the brands, 48 percent of them combinations with nutrients, docusate or ondansetron, and found little justification for adding nutrients (Belcourt 2026).
• A dose without a clinical reason. Nominators argued that some patients need lower or higher doses than the pens deliver. FDA answered that the label already allows a lower maintenance dose and slower titration, that Lilly now sells multi-dose vials and KwikPens from 2.5 to 15 mg, and that a better response at a higher dose does not make the approved product unsuitable (Federal Register, May 2026).
• Preference. FDA's notice put it plainly: the standard is clinical need, not preference, and discomfort with injections does not make the approved product medically unsuitable.

What might qualify

A documented allergy or intolerance to an inactive ingredient is the textbook case, though a narrow one here: FDA lists only sodium chloride, sodium phosphate and water alongside tirzepatide in the single-dose products (Federal Register, May 2026). A route the brands do not offer, such as a sublingual drop, is not a copy under FDA's definition, which is why such products appeared; but no study shows that tirzepatide is absorbed that way, and FDA tentatively found no clinical need to make them in outsourcing facilities. In every case the reason has to be written by the prescriber, about you, before the pharmacy fills it.

Legal or not: the October 2026 map

How to tell which one you are being offered

1. Is it Zepbound or Mounjaro by name? Then it is the approved drug, wherever you buy it with a prescription.
2. If it is compounded, which pharmacy, in which state, and is it 503A or 503B? A 503B source of tirzepatide in 2026 is a red flag in itself.
3. What is your patient-specific reason? Ask the prescriber what it is and whether it is on the prescription. If the answer is that everyone gets the same product, it is a copy.
4. Is the add-in the reason? If every customer gets the vitamin, it is not a reason.
5. What does the marketing say? 'Generic', 'same as Zepbound', 'FDA-approved ingredients' and 'clinically proven' are the phrases the letters quoted.
6. Is a prescription required at all? A vial sold without one, or labeled for research, is not a compounded drug.
7. Check the names. Look up the pharmacy's license with your state board of pharmacy and search FDA's warning-letter database for the company. Our online clinic comparison shows how few programs name their pharmacy.

If FDA finalizes the 503B exclusion

FDA's notice explains the next step: after reviewing comments, it publishes a final determination in the Federal Register, after which it stops considering docket comments; interested parties can still ask it to revisit the decision through a citizen petition (Federal Register, May 2026). Comments closed July 30, 2026, and as of October 9 no final notice had appeared.

If finalized, three things follow. Outsourcing facilities could not compound tirzepatide from bulk drug substance unless it returned to the shortage list, which is the only other route in section 503B. The arguments the nominators made, oral and sublingual forms, combinations with pyridoxine or an antiemetic, doses for 'hyper-responders', would have a formal FDA answer. And office stock for clinics and medical spas, which only 503B facilities may supply without patient prescriptions, would stay closed for tirzepatide. Patient-specific 503A compounding would be untouched, because it rests on a different section of the law. In practice the change is smaller than it sounds: 503B facilities already lost their basis in March 2025. The rule would make that permanent.

The state layer

Federal law decides what may be compounded; states decide who may prescribe it and which pharmacies may make it. A prescription is valid only from a clinician licensed in the state where you are during the visit. State boards license and inspect 503A pharmacies, including out-of-state pharmacies that ship in, and discipline them.

That enforcement is real. In October 2025 Pennsylvania fined Boothwyn Pharmacy $1 million and put its license on probation for compounding roughly 30,000 doses of injectable GLP-1 drugs in rooms the board had never inspected, producing over a thousand doses a day while four inspections passed without staff disclosing it (Pennsylvania Department of State 2025). A secret-shopper study of 75 weight-loss clinics and medical spas in West Virginia and Oklahoma, run from August to October 2025, found 56 percent offering compounded GLP-1s combined with B vitamins; of the compounding facilities supplying them, 4 of 21 were not licensed for sterile compounding and 3 of 22 had faced state discipline since 2023 (DiStefano 2026). The post-shortage market did not disappear; it moved to suppliers that are harder to see.

Bottom line

Compounded tirzepatide is still available in October 2026 in the form the law always allowed: one patient, one documented clinical reason, one licensed 503A pharmacy. The shortage that let pharmacies and outsourcing facilities copy it at scale ended on December 19, 2024, the courts upheld that decision through August 2026, and FDA has spent 2026 enforcing the consequences against marketing, add-in workarounds and research vials, while proposing to close the 503B door for good. If you are offered compounded tirzepatide, the legal question is not whether it is cheaper or 'personalized'; it is whether your prescriber can tell you, in writing, why Zepbound or Mounjaro will not work for you. If the honest answer is price, our tirzepatide cost guide shows how small the gap has become, and our guide to getting tirzepatide prescribed online covers the legitimate routes.

Frequently asked questions

+−Is compounded tirzepatide still available?

Yes, but only in a narrow lane. Since FDA declared the tirzepatide shortage resolved on December 19, 2024, and the grace periods ended in early 2025, a state-licensed 503A pharmacy may compound tirzepatide only for a named patient whose prescriber has documented a change that makes a significant difference for that patient compared with Zepbound or Mounjaro. Outsourcing facilities lost their basis on March 19, 2025. Many telehealth sites still sell compounded tirzepatide to anyone; that is the model FDA's 2026 warning letters targeted.

+−Is compounded tirzepatide legal in 2026?

Legal for an individual patient with a documented, patient-specific reason the approved product will not work, prepared by a licensed 503A pharmacy. Not legal as a routine copy sold to everyone, as a batch product from a 503B outsourcing facility, or as a research vial. A federal appeals court upheld FDA's shortage decision on August 27, 2026, so the shortage-era rules are not coming back through the courts.

+−Is compounded tirzepatide going away?

The mass-market version is shrinking. FDA sent 55 warning letters to telehealth companies over compounded GLP-1 marketing in 2026, warned a large compounding pharmacy in September 2026 that its tirzepatide-niacinamide product was a copy, and proposed on May 1, 2026 to keep tirzepatide off the list outsourcing facilities may use. Patient-specific compounding with a documented clinical reason is written into the statute and is not going away.

+−Was compounded tirzepatide banned in 2026?

No single ban was issued. What happened is that the shortage exception ended in December 2024 and the ordinary rules took over: no routine copies of an approved drug, no 503B batches without a shortage or a listing, no unapproved new drugs. The 2026 actions enforced those rules and proposed making the 503B exclusion permanent; the proposal was not final as of October 9, 2026.

+−Can I still get compounded tirzepatide?

Only if a clinician licensed in your state documents a reason specific to you that Zepbound or Mounjaro cannot meet, and a licensed 503A pharmacy prepares it. Price, convenience, a preference to avoid pens and a wish for a 'custom' dose are not such reasons in FDA's view. For most people the legal and often only slightly more expensive route is brand Zepbound at $299 to $449 a month through the manufacturer's self-pay program.

+−What is the difference between 503A and 503B?

A 503A pharmacy is licensed by a state and compounds for an individual patient on a prescription; FDA does not review its products. A 503B outsourcing facility registers with FDA, follows manufacturing-style quality rules, is inspected by FDA and may make batches without patient prescriptions, but only from substances on FDA's 503B list or for drugs in shortage. Tirzepatide is neither on that list nor in shortage, so 503B facilities have had no basis to make it from bulk powder since March 19, 2025.

+−Is 503A or 503B better?

For quality controls, 503B facilities are held to stricter manufacturing standards and are inspected by FDA. For tirzepatide in 2026 the question is moot: a 503B facility should not be making it from bulk drug substance at all, so a tirzepatide product described as coming from a 503B facility is a reason to ask more questions, not fewer.

+−Does adding B12 make compounded tirzepatide legal?

Not by itself. FDA's April 2026 policy update used semaglutide plus B12 as an example of a product that can still be a copy when the route and strength match the brand, and its September 18, 2026 warning letter to a compounding pharmacy treated tirzepatide with niacinamide as a copy and called the claimed differences 'pretextual' given the volumes produced. An add-in counts only if a prescriber documents why that patient needs it.

+−Where can I buy tirzepatide?

You cannot buy it without a prescription. With one, Mounjaro and Zepbound are dispensed by retail pharmacies, Zepbound is sold for cash through Lilly's self-pay program and listed on the federal TrumpRx site, and a compounded version can be filled by a licensed pharmacy only for a documented individual need. Vials sold online for 'research use' are unapproved drugs, and FDA warned sellers of them in March and August 2026.

Sources

1. SourceUS Court of Appeals for the Fifth Circuit. Outsourcing Facilities Association v. FDA (Eli Lilly, intervenor), No. 25-10600, unpublished per curiam opinion affirming judgment for FDA, August 27, 2026 (companion semaglutide appeal No. 25-10758). (2026)
2. NewsBeaver NA, Rosen DL. GLP-1 drugs: FDA sued over removing tirzepatide from the drug shortage list. Foley and Lardner, October 23, 2024. (2024)
3. NewsFoley and Lardner. GLP-1 drugs: FDA re-confirms decision removing tirzepatide from the drug shortage list (December 19, 2024 declaratory order; enforcement discretion to February 18 and March 19, 2025). December 20, 2024. (2024)
4. NewsBeaver NA, Rosen DL. Compounded GLP-1 drugs: Texas judge denies PI motion and request for stay of FDA's declaration that tirzepatide shortage is resolved; plaintiff OFA appeals. Foley and Lardner, March 12, 2025. (2025)
5. NewsMcDermott Will and Schulte. GLP-1 update: court backs FDA in tirzepatide compounding case (May 7, 2025 ruling, N.D. Tex.). June 13, 2025. (2025)
6. RegulatoryFederal Register. List of bulk drug substances for which there is a clinical need under section 503B: FDA proposes not to include semaglutide, tirzepatide and liraglutide (91 FR 23431, docket FDA-2018-N-3240). May 1, 2026. (2026)
7. RegulatoryFederal Register. 503B bulks list for semaglutide, tirzepatide and liraglutide: extension of comment period to July 30, 2026. June 26, 2026. (2026)
8. RegulatoryFederal Register. Guidance on compounded drug products that are essentially copies of a commercially available drug product under section 503A: information collection notice describing the prescriber's significant-difference determination and its documentation. January 19, 2018. (2018)
9. NewsFrier Levitt. FDA warning letter signals new enforcement theory for compounded GLP-1 combination products (Empower Pharmacy letter of September 18, 2026; FDA policy update of April 1, 2026). September 25, 2026. (2026)
10. NewsFoley and Lardner. GLP-1 compliance: FDA targets telehealth marketing in 30 new warning letters. March 12, 2026. (2026)
11. NewsKlein J. FDA's focus returns to compounding and telehealth: another wave of warning letters (25 letters, week of June 15, 2026). Sheppard Mullin FDA Law Update, June 18, 2026. (2026)
12. NewsArentFox Schiff. RUO-ined: five peptide vendors learn that research use only is not a legal strategy (FDA warning letters of August 24, 2026). September 18, 2026. (2026)
13. RegulatoryPennsylvania Department of State. Chester County pharmacy fined $1 million and placed on probation for compounding approximately 30,000 doses of injectable weight-loss drugs in uninspected facilities. October 21, 2025. (2025)
14. StudyDiStefano MJ et al. Postshortage compounded GLP-1 RA market in 2 states with potentially high demand (secret-shopper study). JAMA Health Forum 2026;7:e262207. (2026)
15. StudyBelcourt J, Sapowadia A, White CM. Compounded semaglutide and tirzepatide products use unique formulations but efficacy and safety largely unknown. Ann Pharmacother 2026;60:902-6. (2026)